These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12113828)

  • 1. N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.
    Inguimbert N; Poras H; Teffo F; Beslot F; Selkti M; Tomas A; Scalbert E; Bennejean C; Renard P; Fournié-Zaluski MC; Roques BP
    Bioorg Med Chem Lett; 2002 Aug; 12(15):2001-5. PubMed ID: 12113828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo properties of thiol inhibitors of the three vasopeptidases NEP, ACE and ECE are improved by introduction of a 7-azatryptophan in P2' position.
    Inguimbert N; Poras H; Dhotel H; Beslot F; Scalbert E; Bennejean C; Renard P; Fournié-Zaluski MC; Roques BP
    J Pept Res; 2004 Feb; 63(2):99-107. PubMed ID: 15009531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
    Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
    Battistini B; Daull P; Jeng AY
    Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
    Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
    J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
    Jullien N; Makritis A; Georgiadis D; Beau F; Yiotakis A; Dive V
    J Med Chem; 2010 Jan; 53(1):208-20. PubMed ID: 19899765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
    Olimpieri F; Tambaro S; Fustero S; Lazzari P; Sanchez-Roselló M; Pani L; Volonterio A; Zanda M
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4715-9. PubMed ID: 19596577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting ACE and ECE with dual acting inhibitors.
    Hanessian S; Guesné S; Riber L; Marin J; Benoist A; Mennecier P; Rupin A; Verbeuren TJ; De Nanteuil G
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1058-62. PubMed ID: 18160283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.
    Fink CA; Moskal M; Firooznia F; Hoyer D; Symonsbergen D; Wei D; Qiao Y; Savage P; Beil ME; Trapani AJ; Jeng AY
    Bioorg Med Chem Lett; 2000 Sep; 10(17):2037-9. PubMed ID: 10987444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition.
    Mellin V; Jeng AY; Monteil C; Renet S; Henry JP; Thuillez C; Mulder P
    J Cardiovasc Pharmacol; 2005 Sep; 46(3):390-7. PubMed ID: 16116347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
    Fink CA; Qiao Y; Berry CJ; Sakane Y; Ghai RD; Trapani AJ
    J Med Chem; 1995 Dec; 38(26):5023-30. PubMed ID: 8544178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Trapani AJ; Beil ME; Bruseo CW; Savage P; Firooznia F; Jeng AY
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S211-5. PubMed ID: 15838282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).
    Inguimbert N; Coric P; Poras H; Meudal H; Teffot F; Fournié-Zaluski MC; Roques BP
    J Med Chem; 2002 Mar; 45(7):1477-86. PubMed ID: 11906289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
    Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
    J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
    Lin CL; Winardi W; Jeng AY; Kwan AL
    Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
    Wallace EM; Moliterni JA; Moskal MA; Neubert AD; Marcopulos N; Stamford LB; Trapani AJ; Savage P; Chou M; Jeng AY
    J Med Chem; 1998 Apr; 41(9):1513-23. PubMed ID: 9554884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of substrate specificity of a new peptide substrate of endothelin converting enzyme].
    Gureeva TA; Kugaevskaia EV; Pozdnev VF; Prozorovskiĭ VN; Eliseeva IuE; Solov'eva NI
    Biomed Khim; 2007; 53(2):172-80. PubMed ID: 17639718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.